Ximena L. Raffo Iraolagoitia

CXCR2 inhibition enables NASH-HCC immunotherapy

Jack Leslie, John B. G. Mackey, Thomas Jamieson et al. · Gut · 2022 · 228 citations · Full text

Medicine, Immunology, Oncology +17

Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma

Nathiya Muthalagu, Tiziana Monteverde, Ximena L. Raffo Iraolagoitia et al. · Cancer Discovery · 2020 · 180 citations · Full text

Medicine, Genetics, Oncology +17

NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells

Ximena L. Raffo Iraolagoitia, Raúl G. Spallanzani, Nicolás I. Torres et al. · The Journal of Immunology · 2016 · 100 citations · Full text

Life Sciences, Immunology, Oncology +17

Human M2 Macrophages Limit NK Cell Effector Functions through Secretion of TGF-β and Engagement of CD85j

Sol Yanel Núñez, Andrea Ziblat, Florencia Secchiari et al. · The Journal of Immunology · 2017 · 89 citations · Full text

Life Sciences, Cell Biology, Immunology +13

IL‐27 stimulates human NK‐cell effector functions and primes NK cells for IL‐18 responsiveness

Andrea Ziblat, Carolina I. Domaica, Raúl G. Spallanzani et al. · European Journal of Immunology · 2014 · 77 citations · Full text

Life Sciences, Cell Biology, Immunology +15